Abstract：
To discern the diagnostic accuracy between the updated diagnostic consensus of the Asian Working Group for Sarcopenia (AWGS) in 2019 (AWGS 2019) and the previous AWGS 2014 guidelines.
A prospective population-based cohort study.
The study included 731 older community-dwelling adults aged ≥ 65 years who participated in face-to-face interviews and were followed up for 11-year mortality until 31 Mar 2022.
We utilized a handgrip strength dynamometer to measure participants\' muscle strength, while their walking speed was determined by a timed 6-meter walk test at their usual pace. Additionally, muscle mass was measured using dual-energy X-ray absorptiometry scanning. Sarcopenia was defined as the presence of low muscle mass in combination with weakness and/or slowness both by AWGS 2014 and 2019 criteria.
The present study followed 731 participants (mean age 73.4 ± 5.4 years, men predominant 52.8%) over a period of 11 years, yielding 5927 person-years and 159 deaths. Prevalence of sarcopenia defined by AWGS 2019 and 2014 criteria were 8.5% and 6.8%, respectively. Sarcopenia defined by AWGS 2019 (HR 1.62, 95% CI 1.04-2.54, p=0.034) but not AWGS 2014 was significantly associated with mortality in community-living older adults after adjusting for potential confounders such as age, sex, education, drinking, disease burden and serum level of testosterone. The study also found that the AWGS 2019 criteria had a better model fitness than AWGS 2014 criteria in predicting mortality.
AWGS 2019 criteria outperformed AWGS 2014 in identifying sarcopenia risk and predicting mortality. Screening for sarcopenia in older adults may improve health outcomes by identifying those at increased mortality risk.
A prospective population-based cohort study.
The study included 731 older community-dwelling adults aged ≥ 65 years who participated in face-to-face interviews and were followed up for 11-year mortality until 31 Mar 2022.
We utilized a handgrip strength dynamometer to measure participants\' muscle strength, while their walking speed was determined by a timed 6-meter walk test at their usual pace. Additionally, muscle mass was measured using dual-energy X-ray absorptiometry scanning. Sarcopenia was defined as the presence of low muscle mass in combination with weakness and/or slowness both by AWGS 2014 and 2019 criteria.
The present study followed 731 participants (mean age 73.4 ± 5.4 years, men predominant 52.8%) over a period of 11 years, yielding 5927 person-years and 159 deaths. Prevalence of sarcopenia defined by AWGS 2019 and 2014 criteria were 8.5% and 6.8%, respectively. Sarcopenia defined by AWGS 2019 (HR 1.62, 95% CI 1.04-2.54, p=0.034) but not AWGS 2014 was significantly associated with mortality in community-living older adults after adjusting for potential confounders such as age, sex, education, drinking, disease burden and serum level of testosterone. The study also found that the AWGS 2019 criteria had a better model fitness than AWGS 2014 criteria in predicting mortality.
AWGS 2019 criteria outperformed AWGS 2014 in identifying sarcopenia risk and predicting mortality. Screening for sarcopenia in older adults may improve health outcomes by identifying those at increased mortality risk.
摘要：
区分亚洲工作组（AWGS）在2019年更新的诊断共识（AWGS2019）和之前的AWGS2014指南之间的诊断准确性。
一项基于人群的前瞻性队列研究。
该研究包括731名年龄≥65岁的老年社区居住成年人，他们参加了面对面的访谈，并随访了11年的死亡率，直到2022年3月31日。
我们使用手握力量测力计来测量参与者的肌肉力量，而他们的步行速度是通过按常规速度进行的6米步行测试来确定的。此外,使用双能X线骨密度仪扫描测量肌肉质量.根据AWGS2014和2019标准，肌肉减少症被定义为存在低肌肉质量与无力和/或缓慢的组合。
本研究随访了731名参与者(平均年龄73.4±5.4岁，男性占52.8%)在11年的时间里，产生5927人年和159人死亡。AWGS2019年和2014年标准定义的肌肉减少症患病率分别为8.5%和6.8%，分别。AWGS2019（HR1.62，95％CI1.04-2.54，p=0.034）定义的肌肉减少症，但AWGS2014在调整了潜在的混杂因素后，与社区生活的老年人的死亡率显着相关，例如年龄，性别,教育,饮酒,疾病负担和血清睾酮水平。该研究还发现，AWGS2019标准在预测死亡率方面比AWGS2014标准具有更好的模型适应性。
AWGS2019标准在识别少肌症风险和预测死亡率方面优于AWGS2014。在老年人中筛查肌肉减少症可以通过确定死亡风险增加的人群来改善健康结果。
一项基于人群的前瞻性队列研究。
该研究包括731名年龄≥65岁的老年社区居住成年人，他们参加了面对面的访谈，并随访了11年的死亡率，直到2022年3月31日。
我们使用手握力量测力计来测量参与者的肌肉力量，而他们的步行速度是通过按常规速度进行的6米步行测试来确定的。此外,使用双能X线骨密度仪扫描测量肌肉质量.根据AWGS2014和2019标准，肌肉减少症被定义为存在低肌肉质量与无力和/或缓慢的组合。
本研究随访了731名参与者(平均年龄73.4±5.4岁，男性占52.8%)在11年的时间里，产生5927人年和159人死亡。AWGS2019年和2014年标准定义的肌肉减少症患病率分别为8.5%和6.8%，分别。AWGS2019（HR1.62，95％CI1.04-2.54，p=0.034）定义的肌肉减少症，但AWGS2014在调整了潜在的混杂因素后，与社区生活的老年人的死亡率显着相关，例如年龄，性别,教育,饮酒,疾病负担和血清睾酮水平。该研究还发现，AWGS2019标准在预测死亡率方面比AWGS2014标准具有更好的模型适应性。
AWGS2019标准在识别少肌症风险和预测死亡率方面优于AWGS2014。在老年人中筛查肌肉减少症可以通过确定死亡风险增加的人群来改善健康结果。
